Who Should Receive HMG CoA Reductase Inhibitors?

During the last decade, the development of the HMG CoA reductase inhibitors, commonly referred to as ‘statins’, has contributed greatly to cholesterol lowering therapy and cardiovascular risk reduction. These agents are well tolerated and efficacious. Data on nearly 30 000 patients from five long-term randomised, placebo-controlled trials of statins have clearly demonstrated that a broad range of individuals can benefit from such therapy. These …